Tarsus Pharmaceuticals announced it has acquired clinical-stage ophthalmic biotechnology company iRenix Medical, adding late-stage investigational therapy IRX-101 to its eye care pipeline. The deal strengthens Tarsus’ presence in retinal disease while expanding beyond its commercial product XDEMVY into therapies designed to improve the patient experience during vision-preserving procedures.
IRX-101 is an investigational ocular antiseptic developed to reduce post-procedural pain and corneal toxicity in patients undergoing intravitreal injections, one of the most common treatments for chronic retinal diseases. According to Tarsus, more than 11 million intravitreal injections are performed annually in the U.S., yet physicians have relied on povidone-iodine as the standard antiseptic for more than four decades despite its association with eye irritation and corneal damage.
The acquisition provides Tarsus with a late-stage clinical asset supported by positive Phase 2b/3 data and an FDA-aligned development plan. The company expects to begin a Phase 3 study during the first half of 2027, with results anticipated in 2028.
In the completed Phase 2b/3 RELIEF trial involving 154 patients, IRX-101 achieved statistically significant improvements over povidone-iodine on both co-primary endpoints. Patients receiving IRX-101 experienced approximately a 50% relative reduction in post-procedural pain, with half reporting no pain following treatment. The study also demonstrated roughly a 25% relative reduction in corneal fluorescein staining, indicating less damage to the corneal surface.
Tarsus believes the therapy could address an unmet need for patients with chronic retinal diseases such as neovascular age-related macular degeneration, diabetic macular edema, retinal vein occlusion-related macular edema, and geographic atrophy, all of which often require injections every four weeks to preserve vision. By reducing discomfort associated with repeated procedures, the company believes IRX-101 could help improve treatment adherence while establishing a foundation for its expansion into retina.
Under the terms of the agreement, Tarsus will pay approximately $75 million upfront, split evenly between $37.5 million in cash and $37.5 million in Tarsus common stock. The agreement also includes up to $490 million in potential regulatory approval and commercial milestone payments tied to the future success of IRX-101.
The transaction reflects Tarsus’ broader strategy of building a diversified eye care company focused on therapies that address underserved areas of ophthalmology. Alongside XDEMVY, the company is advancing TP-04 for ocular rosacea and TP-05 for Lyme disease prevention, both currently in Phase 2 development.
KEY QUOTES:
“With XDEMVY, we demonstrated the importance of meaningful innovation in areas of eye care that had previously been overlooked despite their significant impact on patients. We believe IRX-101 has the potential to do the same for patients with retinal disease who rely on repeated procedures to preserve their vision. By reducing the pain and ocular surface toxicity associated with current antiseptic approaches, IRX-101 has the potential to benefit both patients and physicians while also establishing an important foundation in retina as we continue building a leading eye care company.”
Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus Pharmaceuticals
“Retina specialists have relied on the same antiseptic approach for decades—not because it’s ideal, but because there simply hasn’t been a better alternative. Patients regularly tell us the burning and irritation after treatment are among the most difficult parts of repeated injections. Based on the data generated to date, IRX-101 has the potential to meaningfully improve that experience while maintaining the antiseptic activity physicians depend on. That combination is what makes us so excited about IRX-101.”
David M. Brown, M.D., Chief Medical Officer, Retina Consultants of America
“IRX-101 was developed to improve the treatment experience for patients undergoing repeated retinal procedures. I am incredibly proud of what the iRenix team accomplished in advancing the program into late-stage clinical development and demonstrating its potential to meaningfully improve the patient experience. We believe Tarsus is the ideal company to take IRX-101 through the next stage of development and ultimately bring it to patients. Their track record of identifying important unmet needs in eye care and successfully developing and commercializing innovative therapies gives us confidence in the future of the program.”
Stephen J. Smith, M.D., Chief Executive Officer and Co-Founder of iRenix Medical
